nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—PPARD—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0313	0.0692	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors—NR1I2—bone cancer	0.0286	0.0633	CbGpPWpGaD
Treprostinil—PPARD—Ectoderm Differentiation—BCOR—bone cancer	0.0229	0.0505	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.0226	0.05	CbGpPWpGaD
Treprostinil—P2RY12—Signal amplification—GNA11—bone cancer	0.0215	0.0475	CbGpPWpGaD
Treprostinil—PPARD—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.0199	0.0439	CbGpPWpGaD
Treprostinil—PPARD—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.0183	0.0404	CbGpPWpGaD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—GNA11—bone cancer	0.0123	0.0273	CbGpPWpGaD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0116	0.0258	CbGpPWpGaD
Treprostinil—PPARD—Generic Transcription Pathway—ZNF77—bone cancer	0.0115	0.0255	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0111	0.0246	CbGpPWpGaD
Treprostinil—Infection—Carboplatin—bone cancer	0.00983	0.0179	CcSEcCtD
Treprostinil—Cellulitis—Cisplatin—bone cancer	0.00894	0.0163	CcSEcCtD
Treprostinil—Pain—Carboplatin—bone cancer	0.00846	0.0154	CcSEcCtD
Treprostinil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00816	0.018	CbGpPWpGaD
Treprostinil—Wheezing—Cisplatin—bone cancer	0.0079	0.0144	CcSEcCtD
Treprostinil—Body temperature increased—Carboplatin—bone cancer	0.00782	0.0143	CcSEcCtD
Treprostinil—P2RY12—G alpha (i) signalling events—GRM4—bone cancer	0.00761	0.0168	CbGpPWpGaD
Treprostinil—P2RY12—G alpha (i) signalling events—RGS1—bone cancer	0.00761	0.0168	CbGpPWpGaD
Treprostinil—Hypoxia—Methotrexate—bone cancer	0.00702	0.0128	CcSEcCtD
Treprostinil—Cardiac failure congestive—Cisplatin—bone cancer	0.00651	0.0119	CcSEcCtD
Treprostinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00629	0.0139	CbGpPWpGaD
Treprostinil—PPARD—Presenilin action in Notch and Wnt signaling—JUN—bone cancer	0.00574	0.0127	CbGpPWpGaD
Treprostinil—Haemoptysis—Epirubicin—bone cancer	0.00564	0.0103	CcSEcCtD
Treprostinil—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00562	0.0124	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—ZNF77—bone cancer	0.00556	0.0123	CbGpPWpGaD
Treprostinil—Dehydration—Cisplatin—bone cancer	0.00549	0.01	CcSEcCtD
Treprostinil—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00541	0.012	CbGpPWpGaD
Treprostinil—Hypokalaemia—Cisplatin—bone cancer	0.00537	0.00981	CcSEcCtD
Treprostinil—Haemoptysis—Doxorubicin—bone cancer	0.00522	0.00953	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00501	0.0111	CbGpPWpGaD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—PLAU—bone cancer	0.00498	0.011	CbGpPWpGaD
Treprostinil—Abdominal discomfort—Cisplatin—bone cancer	0.00489	0.00893	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.00488	0.0108	CbGpPWpGaD
Treprostinil—PPARD—NRF2 pathway—GSTP1—bone cancer	0.00487	0.0108	CbGpPWpGaD
Treprostinil—PPARD—NRF2 pathway—TGFBR2—bone cancer	0.00487	0.0108	CbGpPWpGaD
Treprostinil—Rectal haemorrhage—Epirubicin—bone cancer	0.00462	0.00844	CcSEcCtD
Treprostinil—Viral infection—Epirubicin—bone cancer	0.00462	0.00844	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—GRM4—bone cancer	0.00461	0.0102	CbGpPWpGaD
Treprostinil—Cellulitis—Epirubicin—bone cancer	0.00459	0.00838	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00447	0.00987	CbGpPWpGaD
Treprostinil—Pulmonary embolism—Methotrexate—bone cancer	0.00446	0.00815	CcSEcCtD
Treprostinil—Bone pain—Epirubicin—bone cancer	0.00436	0.00796	CcSEcCtD
Treprostinil—Melaena—Methotrexate—bone cancer	0.00436	0.00796	CcSEcCtD
Treprostinil—Rectal haemorrhage—Doxorubicin—bone cancer	0.00428	0.00781	CcSEcCtD
Treprostinil—Viral infection—Doxorubicin—bone cancer	0.00428	0.00781	CcSEcCtD
Treprostinil—Cellulitis—Doxorubicin—bone cancer	0.00425	0.00776	CcSEcCtD
Treprostinil—PTGIR—GPCR ligand binding—GRM4—bone cancer	0.00424	0.00938	CbGpPWpGaD
Treprostinil—Neck pain—Epirubicin—bone cancer	0.00423	0.00772	CcSEcCtD
Treprostinil—Pulmonary embolism—Epirubicin—bone cancer	0.00418	0.00762	CcSEcCtD
Treprostinil—Bradycardia—Cisplatin—bone cancer	0.00416	0.00759	CcSEcCtD
Treprostinil—Melaena—Epirubicin—bone cancer	0.00408	0.00745	CcSEcCtD
Treprostinil—P2RY12—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00405	0.00895	CbGpPWpGaD
Treprostinil—Ecchymosis—Methotrexate—bone cancer	0.00403	0.00737	CcSEcCtD
Treprostinil—Bone pain—Doxorubicin—bone cancer	0.00403	0.00736	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—GRM1—bone cancer	0.00399	0.00883	CbGpPWpGaD
Treprostinil—Neck pain—Doxorubicin—bone cancer	0.00391	0.00714	CcSEcCtD
Treprostinil—PPARD—Generic Transcription Pathway—NR1I2—bone cancer	0.00391	0.00864	CbGpPWpGaD
Treprostinil—Sepsis—Methotrexate—bone cancer	0.00387	0.00707	CcSEcCtD
Treprostinil—Pulmonary embolism—Doxorubicin—bone cancer	0.00386	0.00706	CcSEcCtD
Treprostinil—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00386	0.00853	CbGpPWpGaD
Treprostinil—Cramps of lower extremities—Epirubicin—bone cancer	0.00384	0.007	CcSEcCtD
Treprostinil—Flushing—Cisplatin—bone cancer	0.00379	0.00692	CcSEcCtD
Treprostinil—Ecchymosis—Epirubicin—bone cancer	0.00378	0.00689	CcSEcCtD
Treprostinil—Melaena—Doxorubicin—bone cancer	0.00377	0.00689	CcSEcCtD
Treprostinil—Thrombophlebitis—Methotrexate—bone cancer	0.00374	0.00683	CcSEcCtD
Treprostinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00368	0.00813	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—GRM1—bone cancer	0.00368	0.00813	CbGpPWpGaD
Treprostinil—Sepsis—Epirubicin—bone cancer	0.00362	0.00662	CcSEcCtD
Treprostinil—Erythema—Cisplatin—bone cancer	0.00355	0.00649	CcSEcCtD
Treprostinil—Cramps of lower extremities—Doxorubicin—bone cancer	0.00355	0.00648	CcSEcCtD
Treprostinil—PTGIR—Thromboxane A2 receptor signaling—EGFR—bone cancer	0.00351	0.00776	CbGpPWpGaD
Treprostinil—Thrombophlebitis—Epirubicin—bone cancer	0.0035	0.00639	CcSEcCtD
Treprostinil—Ecchymosis—Doxorubicin—bone cancer	0.00349	0.00638	CcSEcCtD
Treprostinil—Muscle spasms—Cisplatin—bone cancer	0.00342	0.00624	CcSEcCtD
Treprostinil—PPARD—Adipogenesis—RB1—bone cancer	0.00337	0.00745	CbGpPWpGaD
Treprostinil—Sepsis—Doxorubicin—bone cancer	0.00335	0.00612	CcSEcCtD
Treprostinil—Cardiac failure congestive—Epirubicin—bone cancer	0.00334	0.0061	CcSEcCtD
Treprostinil—Ill-defined disorder—Cisplatin—bone cancer	0.0033	0.00602	CcSEcCtD
Treprostinil—Anaemia—Cisplatin—bone cancer	0.00329	0.006	CcSEcCtD
Treprostinil—Thrombophlebitis—Doxorubicin—bone cancer	0.00324	0.00592	CcSEcCtD
Treprostinil—Malaise—Cisplatin—bone cancer	0.00321	0.00585	CcSEcCtD
Treprostinil—Cardiac failure—Epirubicin—bone cancer	0.00311	0.00567	CcSEcCtD
Treprostinil—Cardiac failure congestive—Doxorubicin—bone cancer	0.00309	0.00565	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—JUN—bone cancer	0.00303	0.00671	CbGpPWpGaD
Treprostinil—Pain in extremity—Epirubicin—bone cancer	0.00303	0.00553	CcSEcCtD
Treprostinil—Myalgia—Cisplatin—bone cancer	0.00303	0.00553	CcSEcCtD
Treprostinil—Anxiety—Cisplatin—bone cancer	0.00302	0.00551	CcSEcCtD
Treprostinil—PPARD—Metabolism—NDUFA12—bone cancer	0.003	0.00663	CbGpPWpGaD
Treprostinil—Discomfort—Cisplatin—bone cancer	0.00299	0.00546	CcSEcCtD
Treprostinil—Oedema—Cisplatin—bone cancer	0.0029	0.0053	CcSEcCtD
Treprostinil—Infection—Cisplatin—bone cancer	0.00288	0.00526	CcSEcCtD
Treprostinil—Cardiac failure—Doxorubicin—bone cancer	0.00287	0.00525	CcSEcCtD
Treprostinil—Thrombocytopenia—Cisplatin—bone cancer	0.00284	0.00519	CcSEcCtD
Treprostinil—Tachycardia—Cisplatin—bone cancer	0.00283	0.00517	CcSEcCtD
Treprostinil—Dehydration—Epirubicin—bone cancer	0.00282	0.00515	CcSEcCtD
Treprostinil—P2RY12—GPCR ligand binding—SMO—bone cancer	0.00281	0.00622	CbGpPWpGaD
Treprostinil—Pain in extremity—Doxorubicin—bone cancer	0.0028	0.00512	CcSEcCtD
Treprostinil—Anorexia—Cisplatin—bone cancer	0.00277	0.00505	CcSEcCtD
Treprostinil—Hypokalaemia—Epirubicin—bone cancer	0.00276	0.00504	CcSEcCtD
Treprostinil—PPARD—Gene Expression—FUS—bone cancer	0.00272	0.006	CbGpPWpGaD
Treprostinil—Hypotension—Cisplatin—bone cancer	0.00271	0.00495	CcSEcCtD
Treprostinil—Abdominal discomfort—Methotrexate—bone cancer	0.00268	0.0049	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00264	0.00483	CcSEcCtD
Treprostinil—Influenza—Epirubicin—bone cancer	0.00262	0.00478	CcSEcCtD
Treprostinil—Dehydration—Doxorubicin—bone cancer	0.00261	0.00476	CcSEcCtD
Treprostinil—Paraesthesia—Cisplatin—bone cancer	0.00261	0.00476	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—GRM4—bone cancer	0.0026	0.00576	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—RGS1—bone cancer	0.0026	0.00576	CbGpPWpGaD
Treprostinil—PTGIR—GPCR ligand binding—SMO—bone cancer	0.00259	0.00573	CbGpPWpGaD
Treprostinil—Dyspnoea—Cisplatin—bone cancer	0.00259	0.00472	CcSEcCtD
Treprostinil—Hypokalaemia—Doxorubicin—bone cancer	0.00255	0.00466	CcSEcCtD
Treprostinil—Decreased appetite—Cisplatin—bone cancer	0.00252	0.0046	CcSEcCtD
Treprostinil—Bronchitis—Epirubicin—bone cancer	0.00252	0.0046	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—SPARC—bone cancer	0.00252	0.00556	CbGpPWpGaD
Treprostinil—Pneumonia—Methotrexate—bone cancer	0.00251	0.00458	CcSEcCtD
Treprostinil—Depression—Methotrexate—bone cancer	0.00249	0.00454	CcSEcCtD
Treprostinil—PPARD—Metabolism—NT5C3A—bone cancer	0.00248	0.00549	CbGpPWpGaD
Treprostinil—Pain—Cisplatin—bone cancer	0.00248	0.00453	CcSEcCtD
Treprostinil—Influenza—Doxorubicin—bone cancer	0.00242	0.00443	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—GRM4—bone cancer	0.0024	0.0053	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—RGS1—bone cancer	0.0024	0.0053	CbGpPWpGaD
Treprostinil—Feeling abnormal—Cisplatin—bone cancer	0.00239	0.00437	CcSEcCtD
Treprostinil—Haematuria—Methotrexate—bone cancer	0.00238	0.00435	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—GRM4—bone cancer	0.00236	0.00523	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—RGS1—bone cancer	0.00236	0.00523	CbGpPWpGaD
Treprostinil—Epistaxis—Methotrexate—bone cancer	0.00235	0.0043	CcSEcCtD
Treprostinil—Pneumonia—Epirubicin—bone cancer	0.00235	0.00429	CcSEcCtD
Treprostinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00233	0.00516	CbGpPWpGaD
Treprostinil—Bronchitis—Doxorubicin—bone cancer	0.00233	0.00426	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—SPARC—bone cancer	0.00232	0.00512	CbGpPWpGaD
Treprostinil—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0023	0.00509	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—GNA11—bone cancer	0.0023	0.00509	CbGpPWpGaD
Treprostinil—Body temperature increased—Cisplatin—bone cancer	0.00229	0.00419	CcSEcCtD
Treprostinil—Urinary tract infection—Epirubicin—bone cancer	0.00227	0.00415	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—GRM1—bone cancer	0.00226	0.00499	CbGpPWpGaD
Treprostinil—Haemoglobin—Methotrexate—bone cancer	0.00225	0.00411	CcSEcCtD
Treprostinil—Haemorrhage—Methotrexate—bone cancer	0.00224	0.00409	CcSEcCtD
Treprostinil—Haematuria—Epirubicin—bone cancer	0.00223	0.00407	CcSEcCtD
Treprostinil—Pharyngitis—Methotrexate—bone cancer	0.00222	0.00406	CcSEcCtD
Treprostinil—Epistaxis—Epirubicin—bone cancer	0.0022	0.00402	CcSEcCtD
Treprostinil—Sinusitis—Epirubicin—bone cancer	0.00219	0.004	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—RGS1—bone cancer	0.00218	0.00481	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—GRM4—bone cancer	0.00218	0.00481	CbGpPWpGaD
Treprostinil—Pneumonia—Doxorubicin—bone cancer	0.00217	0.00397	CcSEcCtD
Treprostinil—Bradycardia—Epirubicin—bone cancer	0.00213	0.0039	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—GNA11—bone cancer	0.00212	0.00468	CbGpPWpGaD
Treprostinil—Haemoglobin—Epirubicin—bone cancer	0.00211	0.00385	CcSEcCtD
Treprostinil—Rhinitis—Epirubicin—bone cancer	0.0021	0.00384	CcSEcCtD
Treprostinil—Urinary tract infection—Doxorubicin—bone cancer	0.0021	0.00384	CcSEcCtD
Treprostinil—Haemorrhage—Epirubicin—bone cancer	0.0021	0.00383	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—IL3—bone cancer	0.00209	0.00461	CbGpPWpGaD
Treprostinil—Asthenia—Cisplatin—bone cancer	0.00208	0.0038	CcSEcCtD
Treprostinil—Pharyngitis—Epirubicin—bone cancer	0.00208	0.0038	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—GRM1—bone cancer	0.00208	0.00459	CbGpPWpGaD
Treprostinil—Oedema peripheral—Epirubicin—bone cancer	0.00207	0.00377	CcSEcCtD
Treprostinil—Haematuria—Doxorubicin—bone cancer	0.00206	0.00376	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—GRM1—bone cancer	0.00205	0.00453	CbGpPWpGaD
Treprostinil—Epistaxis—Doxorubicin—bone cancer	0.00204	0.00372	CcSEcCtD
Treprostinil—Sinusitis—Doxorubicin—bone cancer	0.00203	0.0037	CcSEcCtD
Treprostinil—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—bone cancer	0.002	0.00443	CbGpPWpGaD
Treprostinil—Diarrhoea—Cisplatin—bone cancer	0.00199	0.00362	CcSEcCtD
Treprostinil—Bradycardia—Doxorubicin—bone cancer	0.00198	0.00361	CcSEcCtD
Treprostinil—Erythema—Methotrexate—bone cancer	0.00195	0.00356	CcSEcCtD
Treprostinil—Haemoglobin—Doxorubicin—bone cancer	0.00195	0.00356	CcSEcCtD
Treprostinil—Flushing—Epirubicin—bone cancer	0.00195	0.00355	CcSEcCtD
Treprostinil—Rhinitis—Doxorubicin—bone cancer	0.00195	0.00355	CcSEcCtD
Treprostinil—Haemorrhage—Doxorubicin—bone cancer	0.00194	0.00354	CcSEcCtD
Treprostinil—Pharyngitis—Doxorubicin—bone cancer	0.00193	0.00352	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—IL3—bone cancer	0.00192	0.00425	CbGpPWpGaD
Treprostinil—Oedema peripheral—Doxorubicin—bone cancer	0.00191	0.00349	CcSEcCtD
Treprostinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00189	0.00418	CbGpPWpGaD
Treprostinil—Back pain—Methotrexate—bone cancer	0.00189	0.00345	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—GRM1—bone cancer	0.00189	0.00417	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—NR1I2—bone cancer	0.00188	0.00416	CbGpPWpGaD
Treprostinil—Vomiting—Cisplatin—bone cancer	0.00184	0.00337	CcSEcCtD
Treprostinil—Rash—Cisplatin—bone cancer	0.00183	0.00334	CcSEcCtD
Treprostinil—Dermatitis—Cisplatin—bone cancer	0.00183	0.00334	CcSEcCtD
Treprostinil—Erythema—Epirubicin—bone cancer	0.00183	0.00333	CcSEcCtD
Treprostinil—Ill-defined disorder—Methotrexate—bone cancer	0.00181	0.0033	CcSEcCtD
Treprostinil—Anaemia—Methotrexate—bone cancer	0.0018	0.00329	CcSEcCtD
Treprostinil—Flushing—Doxorubicin—bone cancer	0.0018	0.00329	CcSEcCtD
Treprostinil—Tension—Epirubicin—bone cancer	0.00179	0.00327	CcSEcCtD
Treprostinil—Nervousness—Epirubicin—bone cancer	0.00177	0.00324	CcSEcCtD
Treprostinil—Back pain—Epirubicin—bone cancer	0.00177	0.00322	CcSEcCtD
Treprostinil—Malaise—Methotrexate—bone cancer	0.00176	0.00321	CcSEcCtD
Treprostinil—Muscle spasms—Epirubicin—bone cancer	0.00176	0.0032	CcSEcCtD
Treprostinil—Nausea—Cisplatin—bone cancer	0.00172	0.00315	CcSEcCtD
Treprostinil—Cough—Methotrexate—bone cancer	0.0017	0.00311	CcSEcCtD
Treprostinil—Ill-defined disorder—Epirubicin—bone cancer	0.00169	0.00309	CcSEcCtD
Treprostinil—Erythema—Doxorubicin—bone cancer	0.00169	0.00308	CcSEcCtD
Treprostinil—Anaemia—Epirubicin—bone cancer	0.00169	0.00308	CcSEcCtD
Treprostinil—Myalgia—Methotrexate—bone cancer	0.00166	0.00303	CcSEcCtD
Treprostinil—Arthralgia—Methotrexate—bone cancer	0.00166	0.00303	CcSEcCtD
Treprostinil—Chest pain—Methotrexate—bone cancer	0.00166	0.00303	CcSEcCtD
Treprostinil—Tension—Doxorubicin—bone cancer	0.00166	0.00303	CcSEcCtD
Treprostinil—Malaise—Epirubicin—bone cancer	0.00165	0.00301	CcSEcCtD
Treprostinil—Discomfort—Methotrexate—bone cancer	0.00164	0.003	CcSEcCtD
Treprostinil—Nervousness—Doxorubicin—bone cancer	0.00164	0.003	CcSEcCtD
Treprostinil—Syncope—Epirubicin—bone cancer	0.00164	0.00299	CcSEcCtD
Treprostinil—Back pain—Doxorubicin—bone cancer	0.00163	0.00298	CcSEcCtD
Treprostinil—Muscle spasms—Doxorubicin—bone cancer	0.00162	0.00297	CcSEcCtD
Treprostinil—Palpitations—Epirubicin—bone cancer	0.00161	0.00295	CcSEcCtD
Treprostinil—Loss of consciousness—Epirubicin—bone cancer	0.0016	0.00293	CcSEcCtD
Treprostinil—Cough—Epirubicin—bone cancer	0.00159	0.00291	CcSEcCtD
Treprostinil—Infection—Methotrexate—bone cancer	0.00158	0.00289	CcSEcCtD
Treprostinil—Ill-defined disorder—Doxorubicin—bone cancer	0.00157	0.00286	CcSEcCtD
Treprostinil—Anaemia—Doxorubicin—bone cancer	0.00156	0.00285	CcSEcCtD
Treprostinil—Thrombocytopenia—Methotrexate—bone cancer	0.00156	0.00285	CcSEcCtD
Treprostinil—Chest pain—Epirubicin—bone cancer	0.00155	0.00284	CcSEcCtD
Treprostinil—Myalgia—Epirubicin—bone cancer	0.00155	0.00284	CcSEcCtD
Treprostinil—Arthralgia—Epirubicin—bone cancer	0.00155	0.00284	CcSEcCtD
Treprostinil—Anxiety—Epirubicin—bone cancer	0.00155	0.00283	CcSEcCtD
Treprostinil—Discomfort—Epirubicin—bone cancer	0.00154	0.0028	CcSEcCtD
Treprostinil—Malaise—Doxorubicin—bone cancer	0.00152	0.00278	CcSEcCtD
Treprostinil—Anorexia—Methotrexate—bone cancer	0.00152	0.00277	CcSEcCtD
Treprostinil—Syncope—Doxorubicin—bone cancer	0.00151	0.00277	CcSEcCtD
Treprostinil—Palpitations—Doxorubicin—bone cancer	0.00149	0.00273	CcSEcCtD
Treprostinil—Oedema—Epirubicin—bone cancer	0.00149	0.00272	CcSEcCtD
Treprostinil—Hypotension—Methotrexate—bone cancer	0.00149	0.00272	CcSEcCtD
Treprostinil—Loss of consciousness—Doxorubicin—bone cancer	0.00148	0.00271	CcSEcCtD
Treprostinil—Infection—Epirubicin—bone cancer	0.00148	0.0027	CcSEcCtD
Treprostinil—Cough—Doxorubicin—bone cancer	0.00147	0.00269	CcSEcCtD
Treprostinil—Shock—Epirubicin—bone cancer	0.00147	0.00268	CcSEcCtD
Treprostinil—Thrombocytopenia—Epirubicin—bone cancer	0.00146	0.00266	CcSEcCtD
Treprostinil—P2RY12—GPCR downstream signaling—GNA11—bone cancer	0.00145	0.00322	CbGpPWpGaD
Treprostinil—Tachycardia—Epirubicin—bone cancer	0.00145	0.00265	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00145	0.00265	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—SMO—bone cancer	0.00144	0.00319	CbGpPWpGaD
Treprostinil—Insomnia—Methotrexate—bone cancer	0.00144	0.00263	CcSEcCtD
Treprostinil—Arthralgia—Doxorubicin—bone cancer	0.00144	0.00263	CcSEcCtD
Treprostinil—Chest pain—Doxorubicin—bone cancer	0.00144	0.00263	CcSEcCtD
Treprostinil—Myalgia—Doxorubicin—bone cancer	0.00144	0.00263	CcSEcCtD
Treprostinil—Anxiety—Doxorubicin—bone cancer	0.00143	0.00262	CcSEcCtD
Treprostinil—Paraesthesia—Methotrexate—bone cancer	0.00143	0.00261	CcSEcCtD
Treprostinil—Discomfort—Doxorubicin—bone cancer	0.00142	0.00259	CcSEcCtD
Treprostinil—Anorexia—Epirubicin—bone cancer	0.00142	0.00259	CcSEcCtD
Treprostinil—Dyspnoea—Methotrexate—bone cancer	0.00142	0.00259	CcSEcCtD
Treprostinil—Dyspepsia—Methotrexate—bone cancer	0.0014	0.00256	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—RGS1—bone cancer	0.0014	0.00309	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GRM4—bone cancer	0.0014	0.00309	CbGpPWpGaD
Treprostinil—Hypotension—Epirubicin—bone cancer	0.00139	0.00254	CcSEcCtD
Treprostinil—PPARD—Gene Expression—EIF2S1—bone cancer	0.00139	0.00307	CbGpPWpGaD
Treprostinil—Decreased appetite—Methotrexate—bone cancer	0.00138	0.00253	CcSEcCtD
Treprostinil—Oedema—Doxorubicin—bone cancer	0.00138	0.00252	CcSEcCtD
Treprostinil—Fatigue—Methotrexate—bone cancer	0.00137	0.00251	CcSEcCtD
Treprostinil—Infection—Doxorubicin—bone cancer	0.00137	0.0025	CcSEcCtD
Treprostinil—P2RY12—Hemostasis—PLAU—bone cancer	0.00137	0.00303	CbGpPWpGaD
Treprostinil—Pain—Methotrexate—bone cancer	0.00136	0.00249	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00136	0.00248	CcSEcCtD
Treprostinil—Shock—Doxorubicin—bone cancer	0.00136	0.00248	CcSEcCtD
Treprostinil—Thrombocytopenia—Doxorubicin—bone cancer	0.00135	0.00246	CcSEcCtD
Treprostinil—Insomnia—Epirubicin—bone cancer	0.00135	0.00246	CcSEcCtD
Treprostinil—Tachycardia—Doxorubicin—bone cancer	0.00135	0.00246	CcSEcCtD
Treprostinil—PTGIR—GPCR downstream signaling—GNA11—bone cancer	0.00134	0.00296	CbGpPWpGaD
Treprostinil—Paraesthesia—Epirubicin—bone cancer	0.00134	0.00244	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—SMO—bone cancer	0.00133	0.00294	CbGpPWpGaD
Treprostinil—Dyspnoea—Epirubicin—bone cancer	0.00133	0.00243	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—GNA11—bone cancer	0.00132	0.00292	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—IL3—bone cancer	0.00132	0.00292	CbGpPWpGaD
Treprostinil—Anorexia—Doxorubicin—bone cancer	0.00131	0.0024	CcSEcCtD
Treprostinil—Feeling abnormal—Methotrexate—bone cancer	0.00131	0.0024	CcSEcCtD
Treprostinil—Dyspepsia—Epirubicin—bone cancer	0.00131	0.00239	CcSEcCtD
Treprostinil—Gastrointestinal pain—Methotrexate—bone cancer	0.0013	0.00238	CcSEcCtD
Treprostinil—Decreased appetite—Epirubicin—bone cancer	0.0013	0.00236	CcSEcCtD
Treprostinil—Hypotension—Doxorubicin—bone cancer	0.00129	0.00235	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—RGS1—bone cancer	0.00129	0.00284	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GRM4—bone cancer	0.00129	0.00284	CbGpPWpGaD
Treprostinil—Fatigue—Epirubicin—bone cancer	0.00128	0.00235	CcSEcCtD
Treprostinil—Pain—Epirubicin—bone cancer	0.00127	0.00233	CcSEcCtD
Treprostinil—PTGIR—Hemostasis—PLAU—bone cancer	0.00126	0.00279	CbGpPWpGaD
Treprostinil—Abdominal pain—Methotrexate—bone cancer	0.00126	0.0023	CcSEcCtD
Treprostinil—Body temperature increased—Methotrexate—bone cancer	0.00126	0.0023	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00126	0.00229	CcSEcCtD
Treprostinil—Insomnia—Doxorubicin—bone cancer	0.00125	0.00228	CcSEcCtD
Treprostinil—Paraesthesia—Doxorubicin—bone cancer	0.00124	0.00226	CcSEcCtD
Treprostinil—Dyspnoea—Doxorubicin—bone cancer	0.00123	0.00224	CcSEcCtD
Treprostinil—Feeling abnormal—Epirubicin—bone cancer	0.00123	0.00224	CcSEcCtD
Treprostinil—Gastrointestinal pain—Epirubicin—bone cancer	0.00122	0.00222	CcSEcCtD
Treprostinil—PTGIR—Signaling by GPCR—GNA11—bone cancer	0.00122	0.00269	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—IL3—bone cancer	0.00121	0.00268	CbGpPWpGaD
Treprostinil—Dyspepsia—Doxorubicin—bone cancer	0.00121	0.00222	CcSEcCtD
Treprostinil—P2RY12—Signaling Pathways—GRM1—bone cancer	0.00121	0.00268	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—EZH2—bone cancer	0.00121	0.00267	CbGpPWpGaD
Treprostinil—Decreased appetite—Doxorubicin—bone cancer	0.0012	0.00219	CcSEcCtD
Treprostinil—P2RY12—Signaling by GPCR—IL3—bone cancer	0.0012	0.00265	CbGpPWpGaD
Treprostinil—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.0012	0.00265	CbGpPWpGaD
Treprostinil—Fatigue—Doxorubicin—bone cancer	0.00119	0.00217	CcSEcCtD
Treprostinil—Pain—Doxorubicin—bone cancer	0.00118	0.00215	CcSEcCtD
Treprostinil—Body temperature increased—Epirubicin—bone cancer	0.00118	0.00215	CcSEcCtD
Treprostinil—Abdominal pain—Epirubicin—bone cancer	0.00118	0.00215	CcSEcCtD
Treprostinil—Asthenia—Methotrexate—bone cancer	0.00114	0.00209	CcSEcCtD
Treprostinil—Feeling abnormal—Doxorubicin—bone cancer	0.00114	0.00207	CcSEcCtD
Treprostinil—Gastrointestinal pain—Doxorubicin—bone cancer	0.00113	0.00206	CcSEcCtD
Treprostinil—Pruritus—Methotrexate—bone cancer	0.00113	0.00206	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—GRM1—bone cancer	0.00111	0.00246	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL3—bone cancer	0.0011	0.00244	CbGpPWpGaD
Treprostinil—Abdominal pain—Doxorubicin—bone cancer	0.00109	0.00199	CcSEcCtD
Treprostinil—Body temperature increased—Doxorubicin—bone cancer	0.00109	0.00199	CcSEcCtD
Treprostinil—Diarrhoea—Methotrexate—bone cancer	0.00109	0.00199	CcSEcCtD
Treprostinil—PPARD—Metabolism—ENO2—bone cancer	0.00109	0.0024	CbGpPWpGaD
Treprostinil—Asthenia—Epirubicin—bone cancer	0.00107	0.00195	CcSEcCtD
Treprostinil—Pruritus—Epirubicin—bone cancer	0.00105	0.00192	CcSEcCtD
Treprostinil—Dizziness—Methotrexate—bone cancer	0.00105	0.00192	CcSEcCtD
Treprostinil—Diarrhoea—Epirubicin—bone cancer	0.00102	0.00186	CcSEcCtD
Treprostinil—Vomiting—Methotrexate—bone cancer	0.00101	0.00185	CcSEcCtD
Treprostinil—PPARD—Metabolism—DHFR—bone cancer	0.00101	0.00223	CbGpPWpGaD
Treprostinil—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.00101	0.00222	CbGpPWpGaD
Treprostinil—Rash—Methotrexate—bone cancer	0.001	0.00183	CcSEcCtD
Treprostinil—Dermatitis—Methotrexate—bone cancer	0.001	0.00183	CcSEcCtD
Treprostinil—Headache—Methotrexate—bone cancer	0.000997	0.00182	CcSEcCtD
Treprostinil—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000991	0.00219	CbGpPWpGaD
Treprostinil—Asthenia—Doxorubicin—bone cancer	0.000989	0.00181	CcSEcCtD
Treprostinil—Dizziness—Epirubicin—bone cancer	0.000985	0.0018	CcSEcCtD
Treprostinil—Pruritus—Doxorubicin—bone cancer	0.000975	0.00178	CcSEcCtD
Treprostinil—Vomiting—Epirubicin—bone cancer	0.000947	0.00173	CcSEcCtD
Treprostinil—Nausea—Methotrexate—bone cancer	0.000946	0.00173	CcSEcCtD
Treprostinil—Diarrhoea—Doxorubicin—bone cancer	0.000943	0.00172	CcSEcCtD
Treprostinil—PPARD—Metabolism—GNA11—bone cancer	0.000943	0.00209	CbGpPWpGaD
Treprostinil—Rash—Epirubicin—bone cancer	0.000939	0.00172	CcSEcCtD
Treprostinil—Dermatitis—Epirubicin—bone cancer	0.000939	0.00171	CcSEcCtD
Treprostinil—Headache—Epirubicin—bone cancer	0.000933	0.0017	CcSEcCtD
Treprostinil—Dizziness—Doxorubicin—bone cancer	0.000912	0.00166	CcSEcCtD
Treprostinil—Nausea—Epirubicin—bone cancer	0.000885	0.00162	CcSEcCtD
Treprostinil—Vomiting—Doxorubicin—bone cancer	0.000877	0.0016	CcSEcCtD
Treprostinil—Rash—Doxorubicin—bone cancer	0.000869	0.00159	CcSEcCtD
Treprostinil—Dermatitis—Doxorubicin—bone cancer	0.000868	0.00159	CcSEcCtD
Treprostinil—Headache—Doxorubicin—bone cancer	0.000864	0.00158	CcSEcCtD
Treprostinil—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.00086	0.0019	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—CYP3A4—bone cancer	0.000855	0.00189	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SMO—bone cancer	0.000853	0.00189	CbGpPWpGaD
Treprostinil—PPARD—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000851	0.00188	CbGpPWpGaD
Treprostinil—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000848	0.00187	CbGpPWpGaD
Treprostinil—Nausea—Doxorubicin—bone cancer	0.000819	0.0015	CcSEcCtD
Treprostinil—PTGIR—Signaling Pathways—SMO—bone cancer	0.000785	0.00174	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—GNA11—bone cancer	0.00078	0.00173	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—GSTP1—bone cancer	0.000731	0.00162	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ATF1—bone cancer	0.000726	0.0016	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—GNA11—bone cancer	0.000718	0.00159	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL3—bone cancer	0.000708	0.00156	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ATF1—bone cancer	0.000668	0.00148	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL3—bone cancer	0.000651	0.00144	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TGFBR2—bone cancer	0.000605	0.00134	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000603	0.00133	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IGF1R—bone cancer	0.000569	0.00126	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TGFBR2—bone cancer	0.000557	0.00123	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—TP53—bone cancer	0.00055	0.00122	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1R—bone cancer	0.000524	0.00116	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—TP53—bone cancer	0.000506	0.00112	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000499	0.0011	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KIT—bone cancer	0.000413	0.000913	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—BRAF—bone cancer	0.000388	0.000858	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KIT—bone cancer	0.00038	0.00084	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—bone cancer	0.000379	0.000838	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—EGFR—bone cancer	0.000376	0.000832	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—BRAF—bone cancer	0.000357	0.00079	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—EGFR—bone cancer	0.000346	0.000765	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MDM2—bone cancer	0.000325	0.000719	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MDM2—bone cancer	0.000299	0.000662	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—JUN—bone cancer	0.000283	0.000625	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MMP9—bone cancer	0.000275	0.000608	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—JUN—bone cancer	0.00026	0.000575	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MMP9—bone cancer	0.000253	0.00056	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGFR—bone cancer	0.000222	0.000491	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ENO2—bone cancer	0.000219	0.000484	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGFR—bone cancer	0.000205	0.000452	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—DHFR—bone cancer	0.000203	0.000449	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GNA11—bone cancer	0.00019	0.000419	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—bone cancer	0.000187	0.000413	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP3A4—bone cancer	0.000172	0.00038	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—bone cancer	0.000172	0.00038	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000171	0.000378	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTP1—bone cancer	0.000147	0.000325	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—bone cancer	7.62e-05	0.000168	CbGpPWpGaD
